Focus: Septodont is a France-based specialist in dental pharmaceuticals spanning pain management, endodontics, restorative care, and surgical regeneration. The company maintains a focused portfolio of local anesthetics and dental-specific therapeutic agents.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
No open roles listed right now. Follow Septodont to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Alpha-adrenergic reversing agent addressing functional deficits from local anesthesia; patent cliff approaching, signaling revenue erosion risk.
Help build intelligence for Septodont
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Septodont's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Generic local anesthetic stabilizing neuronal membrane; mature, commoditized product with limited differentiation.
Post-LOE local anesthetic product with baseline revenue expectations.
Post-LOE local anesthetic with standard generic market dynamics.
Combination local anesthetic formulation; mature market segment.
Combination bupivacaine formulation; post-LOE generic with stable but limited upside.
Local anesthetic with neuronal membrane stabilization mechanism; mature generic.
Post-LOE local anesthetic with standard generic positioning.
Combination prilocaine formulation; post-LOE product with commodity margins.
NDA product with extended patent protection to 2039; strategic growth driver offsetting ORAVERSE cliff with differentiated clinical positioning.
3 discontinued, 1 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo